AT1 Receptor Antagonist Candesartan Attenuates Genomic Damage in Peripheral Blood Lymphocytes of Patients on Maintenance Hemodialysis Treatment | Zendy

Nicole Schupp | Zendy; Przemysław Rutkowski | Zendy; Katarı́na Šebeková | Zendy; André Klassen | Zendy; Udo Bahner | Zendy; Clemens Grupp | Zendy; A. Heidland | Zendy; Helga Stopper | Zendy

Open Access

AT1 Receptor Antagonist Candesartan Attenuates Genomic Damage in Peripheral Blood Lymphocytes of Patients on Maintenance Hemodialysis Treatment

Author(s) -

Nicole Schupp,

Przemysław Rutkowski,

Katarı́na Šebeková,

André Klassen,

Udo Bahner,

Clemens Grupp,

A. Heidland,

Helga Stopper

Publication year - 2011

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000326805

Subject(s) - candesartan , medicine , angiotensin ii receptor type 1 , angiotensin ii , hemodialysis , endocrinology , dna damage , pharmacology , receptor , chemistry , dna , biochemistry

Angiotensin II (ANG II) and advanced glycation end products (AGEs) exert genotoxic effects in vitro which were prevented by the ANG II type 1 (AT1) receptor blocker, candesartan. In end-stage renal disease (ESRD) the incidence of genomic damage is increased. A stimulation of the renin-angiotensin system and accumulation of AGEs could be involved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research